MX2020000332A - Preparacion que comprende vonoprazan. - Google Patents

Preparacion que comprende vonoprazan.

Info

Publication number
MX2020000332A
MX2020000332A MX2020000332A MX2020000332A MX2020000332A MX 2020000332 A MX2020000332 A MX 2020000332A MX 2020000332 A MX2020000332 A MX 2020000332A MX 2020000332 A MX2020000332 A MX 2020000332A MX 2020000332 A MX2020000332 A MX 2020000332A
Authority
MX
Mexico
Prior art keywords
vonoprazan
organic acid
salt
preparation
acid salt
Prior art date
Application number
MX2020000332A
Other languages
English (en)
Inventor
Hiroyuki Fujii
Akira Suzuki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63209641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020000332(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020000332A publication Critical patent/MX2020000332A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención tiene por objeto proporcionar una preparación de la que se espera que mejore el sabor amargo de una sal de ácido orgánico de vonoprazán y permita una rápida disolución de la sal de ácido orgánico de vonoprazán después de la administración. La presente invención proporciona una preparación que contiene gránulos finos o gránulos que contienen una sal de ácido orgánico de vonoprazán, (2) una capa intermedia que contiene el mismo ácido orgánico que el ácido orgánico que forma la sal de vonoprazán en (1), o una de sus sales, y (3) una capa de recubrimiento que contiene un polímero insoluble en agua.
MX2020000332A 2017-07-10 2018-07-09 Preparacion que comprende vonoprazan. MX2020000332A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017135046 2017-07-10
PCT/JP2018/026416 WO2019013310A1 (en) 2017-07-10 2018-07-09 PREPARATION COMPRISING VONOPRAZAN

Publications (1)

Publication Number Publication Date
MX2020000332A true MX2020000332A (es) 2020-07-13

Family

ID=63209641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000332A MX2020000332A (es) 2017-07-10 2018-07-09 Preparacion que comprende vonoprazan.

Country Status (16)

Country Link
US (1) US11696893B2 (es)
EP (1) EP3651735B1 (es)
JP (1) JP7228535B2 (es)
KR (1) KR20200026964A (es)
CN (1) CN110831579A (es)
AR (1) AR112269A1 (es)
BR (1) BR112020000318A2 (es)
CA (1) CA3069563A1 (es)
CO (1) CO2020000490A2 (es)
EC (1) ECSP20009533A (es)
ES (1) ES2921931T3 (es)
MX (1) MX2020000332A (es)
PE (1) PE20200442A1 (es)
PH (1) PH12020500068A1 (es)
SG (1) SG11202000136YA (es)
WO (1) WO2019013310A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109900822A (zh) * 2019-03-12 2019-06-18 康诚科瑞医药研发(武汉)有限公司 一种血浆中沃诺拉赞的定量检测方法
CN110538153B (zh) * 2019-09-26 2022-04-26 扬子江药业集团四川海蓉药业有限公司 一种高稳定性、快速释放的固体制剂及其制备方法
CN113633616A (zh) * 2020-05-11 2021-11-12 鲁南制药集团股份有限公司 一种生物利用度高的固体制剂
US11767311B2 (en) 2020-06-17 2023-09-26 Ildong Pharmaceutical Co., Ltd. Acid secretion inhibitor and use thereof
CN111973565A (zh) * 2020-07-07 2020-11-24 南京海纳医药科技股份有限公司 一种含有富马酸沃诺拉赞的片剂及其溶出度测定方法
CN112353802A (zh) * 2020-11-26 2021-02-12 山东诚创蓝海医药科技有限公司 一种富马酸伏诺拉生掩味组合物及其应用
CN113390983B (zh) * 2021-05-26 2022-06-07 株洲千金药业股份有限公司 一种同时测定富马酸伏诺拉生中3种杂质的检测方法
CN113827574A (zh) * 2021-10-18 2021-12-24 沈阳药科大学 一种富马酸沃诺拉赞口腔速溶片及其制备方法
CN117503707A (zh) * 2022-08-05 2024-02-06 哈尔滨市康隆药业有限责任公司 一种掩味微球及其制备工艺和应用
CN116966180B (zh) * 2022-11-10 2024-05-14 山东道合药业有限公司 沃诺拉赞焦谷氨酸盐的片剂、注射剂、复方制剂
CN115721611A (zh) * 2022-12-09 2023-03-03 北京斯利安药业有限公司 富马酸伏诺拉生干混悬剂及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH072761B2 (ja) 1985-03-20 1995-01-18 不二パウダル株式会社 微結晶セルロ−ス球形顆粒及びその製造法
EP1787640A4 (en) 2004-04-30 2012-04-11 Astellas Pharma Inc GRAINED PHARMACEUTICAL COMPOSITION WITH TEMPORARY DELIVERY FOR ORAL ADMINISTRATION AND FAST-DECREASING INTRAORAL TABLET WITH THE COMPOSITION
ES2402362T3 (es) 2004-09-30 2013-05-03 Takeda Pharmaceutical Company Limited Inhibidores de la bomba de protones
ME00610B (me) 2005-08-30 2011-12-20 Takeda Pharmaceuticals Co 1 –heterociklilsulfonil, 2 –aminometil, 5– (hetero–) aril supstituisan 1–h–pirol derivati kao inhibitori lučenja kiseline
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
BRPI0820997A2 (pt) 2007-12-10 2014-12-23 Eurand Inc Comprimidos de desintegração oral compreendendo difenidramina.
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition
PE20141174A1 (es) 2008-08-27 2014-09-19 Takeda Pharmaceutical Compuestos de pirrol como inhibidores de la bomba de protones
SG10201602311XA (en) * 2010-12-27 2016-04-28 Takeda Pharmaceutical Orally disintegrating tablet
US9487485B2 (en) 2013-02-28 2016-11-08 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound
MA41850A (fr) 2015-03-31 2018-02-06 Takeda Pharmaceuticals Co Nouvelles utilisations pharmaceutiques
EP3636283A1 (en) 2015-06-04 2020-04-15 Pfizer Inc Solid dosage forms of palbociclib
WO2017018473A1 (ja) 2015-07-30 2017-02-02 武田薬品工業株式会社 錠剤
CN105030725B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶组合物及其制备方法
CN105030720B (zh) * 2015-08-26 2019-12-10 迪沙药业集团有限公司 一种富马酸沃诺拉赞肠溶片及其制备方法
CN105663096B (zh) * 2016-01-25 2019-06-14 南京济群医药科技股份有限公司 一种沃诺拉赞口腔速溶膜剂及其制备方法
JP2017135046A (ja) 2016-01-29 2017-08-03 株式会社荏原製作所 検査装置

Also Published As

Publication number Publication date
ECSP20009533A (es) 2020-04-22
US11696893B2 (en) 2023-07-11
CO2020000490A2 (es) 2020-02-28
JP7228535B2 (ja) 2023-02-24
CA3069563A1 (en) 2019-01-17
EP3651735B1 (en) 2022-04-13
TW201907919A (zh) 2019-03-01
RU2020105670A (ru) 2021-08-10
ES2921931T3 (es) 2022-09-02
KR20200026964A (ko) 2020-03-11
SG11202000136YA (en) 2020-02-27
WO2019013310A1 (en) 2019-01-17
US20200163881A1 (en) 2020-05-28
AR112269A1 (es) 2019-10-09
JP2020526486A (ja) 2020-08-31
RU2020105670A3 (es) 2021-10-26
EP3651735A1 (en) 2020-05-20
PE20200442A1 (es) 2020-02-28
CN110831579A (zh) 2020-02-21
BR112020000318A2 (pt) 2020-07-14
PH12020500068A1 (en) 2020-09-28

Similar Documents

Publication Publication Date Title
PH12020500068A1 (en) Preparation comprising vonoprazan
IL245117A0 (en) Co-crystals of (n - (s-methyl-8-(1((2'-methyl-['4,5-bipyrimidine]-6-yl)amino)propane-2-yl)quinoline-4-carboxamide, Derivatives modified by their deuterium, methods for their preparation, preparations containing them and their uses
WO2015165413A8 (zh) 一种新型的稳定型抗体药物耦联物及其制备方法和用途
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
WO2013129889A3 (ko) 실데나필을 유효성분으로 함유하며 고미가 은폐된 고함량 속용필름
EP3412292B8 (en) Use of methoxatin, derivative and/or salt thereof in sjogren's syndrome and pharmaceutical composition
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
MX2017000041A (es) Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos.
WO2019108021A3 (ko) 토파시티닙을 포함하는 약제학적 조성물
MX2015017202A (es) Formulacion de liberacion modificada.
AP2014007866A0 (en) Water-soluble granule formulation of 2,4-D salt and preparation method thereof
TN2016000121A1 (en) Cyclic thienouracil-carboxamides and use thereof
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
MX2019010228A (es) Composición para liberación controlada de sustancias fisiológicamente activas y proceso para su preparación.
EP3295932A3 (en) Stable odf composition containing hardly soluble therapeutic agent
WO2014144407A8 (en) Dual use oral pharmaceutical composition tablets of sulfate salts and methods of use thereof
EP3648745A4 (en) PHARMACEUTICAL COMPOSITION CONSISTING OF A MULTI-UNIT SPHEROIDAL TABLET CONTAINING ESOMEPRAZOLE AND A PHARMACEUTICAL SALT OF THE SAME, AND PROCESS FOR THE PREPARATION OF THE PHARMACEUTICAL COMPOSITION
WO2016093554A3 (ko) 신규한 4-(아릴)-n-(2-알콕시티에노[3,2-b]피라진-3-일)-피페라진-1-카복스아미드 유도체 및 이의 항증식 효과
PH12014502407A1 (en) New alfentanil composition for the treatment of acute pain
SG11201902588PA (en) N3-Cyclically Substituted Thienouracils And Use Thereof
EA201990129A1 (ru) Таблетированный состав с улучшенным профилем растворения для лечения болезни паркинсона
MX2017004032A (es) Composicion farmaceutica solida que comprende amlodipino y losartan.
JP2017008001A5 (es)
EP3593805A4 (en) USE OF A VITAMIN COMPOSITION IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE PREVENTION, TREATMENT OR DELAY OF ALZHEIMER'S DISEASE
WO2016091805A3 (de) Naloxon-monopräparat und mehrschichttablette